Q3 2023 Results

Company overview Financial review Conclusions Appendix References Delivered a very strong quarter, upgraded FY 2023 guidance. Maintaining our commitment to shareholder value creation Very strong Q3: sales +12%, core operating income +21% (cc, continuing operations) Growth drivers continue to perform well in the market: incl. KesimptaⓇ, EntrestoⓇ, KisqaliⓇ and PluvictoⓇ Robust pipeline: innovation milestones for Cosentyx®, PluvictoⓇ, iptacopan, remibrutinib, LutatheraⓇ Successfully completed the Sandoz spin-off: focusing on our core business of innovative medicines Raising 2023 FY guidance 29 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation